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Correspondence
Response: Letter regarding “The prognostic value of p16 and p53 expression for survival after
vulvar cancer: A systematic review and meta-analysis”
We thank Jiang et al. for their interest and their comments to our
systematic review and meta-analysis of the prognostic value on p16 and
p53 expression for survival after vulvar cancer.
Jiang et al. state that we have included duplicated studies in our
meta-analysis and specifically mention two references - both by
(Sznurkowski et al., 2016, 2017). As described in our paper (Sand et al.,
2019) in the paragraph “Search results”, these studies have indeed
overlapping study populations, but report different survival outcomes
(overall survival and disease free survival, respectively), and were
therefore both included in the paper. However, only one of the studies
(Sznurkowski et al., 2016) was included in the calculated pooled esti-
mate on overall survival according to p16 status. In our paper, over-
lapping study populations have systematically been identified and ex-
cluded as appropriate, therefore, to the best of our knowledge, no
duplicate studies have been included in the meta-analysis.
In addition, we evaluated the quality of all studies based on
Reporting Recommendations for Tumor Marker Prognostic Studies
(REMARK) (Altman et al., 2012; McShane et al., 2005). The evaluation
criteria are included in supplementary tables and the scores are in-
cluded in Tables 1 and 3 in the main text (Sand et al., 2019). Most
studies were of good quality, and we did not exclude any studies based
on quality score alone. Finally, we agree with Jiang et al. about the
importance of describing inclusion and exclusion criteria.
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